Paul, who has worked as a senior executive in the healthcare industry for over 40 years, will play an active role in advising CorTechs Labs on matters including, but not limited to, business development strategy as well as product development and enhancement.
Mirabella is currently president and chief executive officer of Paul J. Mirabella Investments and Consulting, LLC, where he oversees consulting and investments in the medical device industry and medical diagnostics.
He is actively involved in developing imaging solutions to reduce radiation exposure as well as artificial intelligence applications in a range of healthcare sectors, with a current focus in neurology.
Previously, he served as president and CEO of GE Healthcare Global Diagnostic Imaging Business and the Global Services Business.
More recently, he was a key investor in and served as chairman and CEO of Naviscan, Inc., developer of a high resolution, organ-specific PET scanner. He also held four of the original patents in computed tomography.
Paul Mirabella holds a bachelor's of science in aerospace engineering and applied mechanics from the Polytechnic Institute of Brooklyn (now NYU) and a master's in mechanical engineering from the University of Central Florida. He has been a guest lecturer on leadership at the University of California, San Diego Rady School of Management.
CorTechs Labs develops and markets medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business